The impact of COVID-19 on hepatitis B and C virus prevention, diagnosis, and treatment in Bangladesh compared with Japan and the global perspective
-
Published:2023-10-23
Issue:1
Volume:23
Page:
-
ISSN:1472-6963
-
Container-title:BMC Health Services Research
-
language:en
-
Short-container-title:BMC Health Serv Res
Author:
Hussain Md Razeen Ashraf,Ali Mohammad,Sugiyama Aya,Hiebert Lindsey,Rahman M. Anisur,Azam Golam,Ouoba Serge,E Bunthen,Ko Ko,Akita Tomoyuki,Ward John W.,Tanaka Junko
Abstract
Abstract
Aim
This study aimed to assess the effect of COVID-19 on hepatitis-related services in Bangladesh and compared the situation with same study conducted in Japan and globally.
Methods
We conducted an online cross-sectional questionnaire survey among the clinicians of four societies associated with liver disease in Bangladesh from October to December 2022. The questionnaire included the same questions as a survey conducted in Japan and globally.
Results
A total of 83 clinicians from 8 divisions in Bangladesh participated; 66.3% were heads of departments/institutions. Except for HCV treatment initiation, more than 30% of clinicians reported a 76–99% decline in all services. Compared to Japan and the global survey, there was a significantly higher decline in all HBV and HCV services in Bangladesh. To resume services back to pre-COVID-19 levels, Patient anxiety and fear (Bangladesh Survey: 80.7% vs Japan Survey: 67.4% vs Global Survey: 37.9%, p < 0.0001), loss of space due to COVID-19 (Bangladesh Survey: 63.9% vs Japan Survey: 34.7% vs Global Survey: 19.4%, p < 0.0001) were the main challenges. As part of the mitigation strategy, usage of telemedicine (Bangladesh Survey: 83.1% vs. Japan Survey: 67.3% vs Global Survey: 78.6% p < 0.0001), COVID-19 benefits, such as increased laboratory testing platforms (Bangladesh Survey: 77.1% vs Japan Survey: 17.9% vs Global Survey: 41.8%, p < 0.0001) was reported significantly higher in Bangladesh than in Japan and global survey.
Conclusion
All the services-related to HBV and HCV were highly affected during greatest impact month of COVID-19 in Bangladesh and the decline level was higher than Japan and global survey. Repeated countermeasures of COVID-19 and constrained healthcare-system were the probable reasons in Bangladesh. Positive impact resulting from COVID-19 countermeasures should be utilized in the national hepatitis program in Bangladesh.
Funder
Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: WHO; 2021.
2. World Health Organization. Global Hepatitis Report 2017. Geneva: WHO; 2017.
3. World Health Organization. Global health sectors strategy on Viral Hepatitis 2016–2021. Towards Ending Viral Hepatitis. Geneva: WHO; 2016.
4. Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, Salam MA, Hassan MS, Beglinger C, Gyr N. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka. Bangladesh BMC Infect Dis. 2010;10:208.
5. Rahman M, Amanullah, Sattar H, Rahman M, Rashid HA, Mollah AS. Sero-epidemiological study of hepatitis B virus infection in a village. Bangladesh Med Res Counc Bull. 1997;23(2):38–41.